Morgan Stanley
ENGN icon

Morgan Stanley’s enGene Therapeutics ENGN Stock Holding History

Morgan Stanley’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.2K Sell
33,086
-53,514
-62% -$218K ﹤0.01% 6456
2026
Q1 		$590K Sell
86,600
-631,885
-88% -$5.63M ﹤0.01% 5407
2025
Q4 		$6.49M Buy
718,485
+283,194
+65% +$2.27M ﹤0.01% 3980
2025
Q3 		$2.97M Buy
435,291
+82,523
+23% +$376K ﹤0.01% 4533
2025
Q2 		$1.28M Sell
352,768
-83,796
-19% -$314K ﹤0.01% 4979
2025
Q1 		$1.96M Sell
436,564
-2,208
-0.5% -$13.7K ﹤0.01% 4614
2024
Q4 		$2.92M Buy
438,772
+430,579
+5,255% +$3.34M ﹤0.01% 4425
2024
Q3 		$54.1K Buy
8,193
+8,135
+14,026% +$60.5K ﹤0.01% 6196
2024
Q2 		$547 Buy
58
+50
+625% +$641 ﹤0.01% 7220
2024
Q1 		$136 Hold
8
– – ﹤0.01% 7345
2023
Q4 		$74 Buy
+8
New +$71 ﹤0.01% 7388

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Morgan Stanley's ENGN Position: Q2 2026 in Review

Morgan Stanley reduced its enGene Therapeutics (ENGN) stake by 62% in Q2 2026, selling an estimated $218K and leaving 33,086 shares worth $57.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6456.

Morgan Stanley first reported a position in ENGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $6.49M in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Morgan Stanley held 33,086 shares of enGene Therapeutics worth $57.2K as of Q2 2026.
  • Morgan Stanley sold 53,514 enGene Therapeutics shares in Q2 2026, an estimated $218K.
  • enGene Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6456 holding.
  • Morgan Stanley first reported a position in enGene Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Morgan Stanley's enGene Therapeutics position peaked at $6.49M in Q4 2025.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.